Intravenous and Inhaled Antimicrobials at Home in Cystic Fibrosis Patients. (May 2014)

• Record Type: Journal Article
• Authors: Thigpen, Jim; Odle, Brian
• Is Part Of: Home health care management & practice. Volume 26:Number 2(2014:May)
• Page Start: 101
• Page End: 109
• Publication Date: 2014-05
• Subjects: cystic fibrosis -- antimicrobial therapy -- intravenous antibiotics -- aerosolized antibiotics -- home health -- Pseudomonas aeruginosa -- Staphylococcus aureus; Home care services -- Periodicals; 649
• DOI: 10.1177/1084822313501322
• Languages: English
• ISSNs: 1084-8223

Abstract

The primary clinical characteristics of cystic fibrosis (CF) are malnutrition caused by malabsorption secondary to pancreatic insufficiency, chronic pulmonary infections, and male infertility. The major cause of morbidity and mortality are bronchiectasis and obstructive pulmonary disease. Lung disease in CF is manifested by this chronic lung disease progression, with intermittent episodes of acute worsening of symptoms called pulmonary exacerbations. Once the patient has stabilized, and if suitable care can be arranged, these interventions are often transitioned to the home. This review summarizes important points pertinent to the use of intravenous and inhaled antimicrobials that may be encountered by prescribers, nurses, technicians, and case managers in the home health setting. Appropriate dosing, indications, adverse drug reactions, monitoring parameters, and practicality of both intravenous and inhaled antimicrobials are discussed.